Medidata, a Dassault Systèmes company, announced that SHYFT Analytics will officially be adopting the Acorn AI, by Medidata brand. The innovative commercial and data analytics technologies and services valued by SHYFT customers will be operating as the Commercial Data Solutions (CDS) team at Acorn AI. SHYFT Analytics was acquired by Medidata in 2018.

Acorn AI, built on data, AI technologies and domain expertise developed over the last 20 years by Medidata, helps life sciences companies answer the questions that matter. Current solutions include:

• Intelligent Trials to improve study success by providing real-time operational insights
• Synthetic Control Arms for diseases where a randomized control is not feasible
• Trial Design that brings together insights from historic clinical trials and contemporaneous real-world use to improve overall probability of success
• Commercial Data Solutions that help therapies accelerate launch and peak patient adoption

“We are excited to bring our combined capabilities to customers under a unified Acorn AI brand,” said Sastry Chilukuri, president, Acorn AI by Medidata. “Scientific breakthroughs continue to create more precise drugs that target specific patient characteristics. This is changing the commercialization paradigm, connecting R&D and Commercial in new ways. Our live platform provides industry leading capabilities to combine Clinical and Real-world insights and help customers accelerate their therapies to patients.”

Acorn AI’s Commercial Data Solutions team is led by Bruno Lempernesse, who was previously CEO of Inflexxion, a technology software SaaS solutions company with clinical assessment tools, Real World Clinical Data and predictive analytics used by healthcare organizations, providers, pharmaceutical companies and regulatory authorities in the space of substance use disorders, like opioid addiction.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

Original News Publication - CIMdata News

Date - 20th August, 2020